Related Experiment Video
Updated: Jan 15, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective
Hong Chen1, Yuan Zhao1, Zhiyu Zhang1
1Beijing Chaoyang Hospital, Capital Medical University, Department of Pathology, Beijing, 100043, China.
Background:
This study aimed to analyze the expressions of CD184 and CD269 in patients with newly diagnosed multiple myeloma (MM) in China and explored their potential association with prognosis.
Methods:
This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves.
Results:
Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P<0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P<0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients.
Conclusions:
CD184 and CD269 may serve as valuable prognostic markers in MM patients.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
07:53Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
